Efinopegdutide

Efinopegdutide (MK-6024) is Merck's Phase 2 peptide drug for MASH, a fatty liver disease that scars the organ over time. (Note on nomenclature: this disease was recently renamed from NASH/NAFLD to MASH/MASLD in the 2023 AASLD consensus; the terms are used interchangeably in medical literature and throughout this writeup.) It hits two hormone receptors at once: GLP-1 (the target behind Ozempic and Wegovy) and glucagon (a metabolic switch that burns fat). Merck licensed the molecule from Korea's Hanmi Pharmaceutical in 2020 for $10M upfront plus up to $860M in potential milestones, betting that combining appetite suppression with direct liver fat oxidation would beat pure GLP-1 drugs on this specific disease [1]. The bet paid off in Phase 2a: efinopegdutide cut liver fat by 72.7% versus 42.3% for semaglutide over 24 weeks (both figures are relative reductions from baseline in MRI-PDFF, a scan that measures the fraction of the liver occupied by fat), though the trial did not include biopsy endpoints [1]. Three Phase 2b studies covering precirrhotic MASH (n=381), compensated cirrhosis (n=85), and dose optimization (n=124) have now completed, positioning Merck for a Phase 3 decision against a market that already has one approved drug (Madrigal's resmetirom) and a crowded pipeline of incretin combos.

Novel investigational compound, never approved anywhere. Efinopegdutide sits in Phase 2 across three parallel Merck-sponsored trials, all recently completed per ClinicalTrials.gov [2][3][4]. No FDA breakthrough therapy or fast track designation has been publicly disclosed by Merck. The lead precirrhotic MASH study (NCT05877547, MK-6024-013) enrolled 381 patients with F2-F3 fibrosis (on the 0 to 4 METAVIR staging scale, meaning significant to severe scarring but not yet cirrhosis) and reads out on histology at Week 52 [2]. A separate cirrhosis study (NCT06465186, MK-6024-017) enrolled 85 patients with compensated cirrhosis (severe scarring but the liver is still functionally intact, no ascites or encephalopathy) due to steatohepatitis and used MRI-PDFF liver fat change at Week 28 as its primary endpoint [3]. A third alternate-dosing study (NCT06482112) tested weight-based regimens in 124 MASLD patients [4]. Timeline for the Phase 3 go/no-go decision hinges on the NCT05877547 histology readout, which had not appeared in a peer-reviewed publication as of the most recent Merck 10-K filed February 2026 [5]. As of this writeup (September 2026), no top-line release from AASLD 2025 or EASL 2026 has surfaced in public search either, so the next likely disclosure window is a late-breaker slot at AASLD 2026 (November) or H1 2027. Merck's silence through two major hepatology meetings post-completion is itself a mild negative signal, though not conclusive.

Two hormones, one peptide. GLP-1 is a gut hormone released after meals that tells the brain you're full and slows how fast food leaves the stomach. Drugs that mimic it, like semaglutide, drive substantial weight loss and improve blood sugar. Glucagon does the opposite of insulin in the fasted state: it tells the liver to release stored energy, and at the right dose it also cranks up whole-body energy expenditure and directly stimulates the liver to burn its own fat stores. Pure glucagon would raise blood sugar to dangerous levels, but pairing it with GLP-1 counterbalances that effect while keeping the fat-burning benefit [6]. Efinopegdutide is a PEGylated peptide, meaning it has a polyethylene glycol chain attached that slows kidney clearance and enables weekly dosing. The mechanism has strong biological backing. GLP-1 monotherapy already reduces liver fat and improves MASH histology in placebo-controlled trials [6]. The glucagon arm adds direct hepatic fat oxidation, which is why efinopegdutide beat semaglutide by roughly 30 percentage points on relative liver fat reduction in head-to-head Phase 2a testing [1]. Boehringer's survodutide, a related dual agonist, showed 83% MASH resolution at high dose in Phase 2, validating the class independently [7]. Altimmune's pemvidutide, another GLP-1/glucagon dual agonist, has also reported Phase 2 MASH activity, further supporting the mechanism class.

The pivotal Phase 2b readout comes from NCT05877547 (MK-6024-013), a 381-patient study in precirrhotic MASH (biopsy-confirmed F2-F3 fibrosis on the 0 to 4 METAVIR scale) with a primary endpoint of MASH resolution without worsening of fibrosis at Week 52 [2]. That is the FDA-recognized histology composite that supported resmetirom's accelerated approval, so the endpoint choice signals Merck's regulatory intent. NCT06465186 (MK-6024-017) took a different angle: 85 patients with compensated cirrhosis (severe liver scarring but the organ still performs its synthetic and detoxification functions) due to steatohepatitis, reading out on MRI-PDFF (proton density fat fraction, a non-invasive MRI technique that quantifies the fat percentage of liver tissue) at Week 28 [3]. Cirrhosis is the highest-value MASH population, where mortality risk is real and no approved drug has demonstrated fibrosis reversal at that stage. Enrollment of only 85 is small for statistical power on histology, so this trial is likely a mechanistic and safety bridge rather than a registration attempt. NCT06482112 explored weight-based dosing in 124 MASLD patients to inform Phase 3 dose selection [4]. All three studies are Merck-sponsored, completed as of mid-2026, and use MRI or biopsy as the primary readout rather than surrogate blood markers. The 52-week histology endpoint on 381 patients is well-powered for MASH resolution but underpowered for the harder fibrosis-improvement endpoint that resmetirom hit.

Our model estimates a 7% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 23%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by the sponsor's strong record of getting drugs approved; it is held back by weak or limited earlier-phase results, a randomized design, and a comparator/control arm. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Four failure modes, roughly in order of severity. First, fibrosis endpoint miss: liver fat reduction is easy for potent GLP-1 based drugs, but fibrosis improvement at 52 weeks is a different biology and has broken multiple prior programs. Efinopegdutide's Phase 2a study was only 24 weeks and did not include biopsy, so the fibrosis question is genuinely open. Second, GI tolerability at MASH-effective doses. GLP-1/glucagon dual agonists produce more nausea and vomiting than pure GLP-1 drugs at matched weight loss, which can force dose reductions that undercut efficacy. Discontinuation rates in NCT06482112's alternate-dosing arms will be a leading indicator. Third, hyperglycemia risk from the glucagon component in non-diabetic MASH patients. Efinopegdutide raised fasting glucose modestly in Phase 2a; scaling that signal in cirrhotic patients with impaired liver metabolism could be problematic [3]. Fourth, commercial displacement. Even a clean approval walks into a crowded market. Resmetirom has a first-mover lock. Tirzepatide's SYNERGY-NASH readout of up to 73.3% MASH resolution at 15 mg (vs 13.2% placebo, 52 weeks) sets a very high bar, and Eli Lilly has cardiovascular outcomes claims that Merck lacks [10]. Semaglutide has strong MASH data plus its own CV claims. Boehringer's survodutide is on a similar Phase 3 timeline with better-published Phase 2 data. Altimmune's pemvidutide is a direct GLP-1/glucagon mechanism competitor with its own Phase 2 MASH dataset. Payer coverage for a fifth or sixth MASH option without a differentiated fibrosis story would be tepid.

Worth watching, not urgent. The signal that moves this from noise to news is the NCT05877547 Week 52 histology readout: MASH resolution rate and fibrosis improvement rate versus placebo, with the resmetirom Phase 3 results (about 26% MASH resolution, 24% fibrosis improvement) as the mental benchmark [9]. Anything above 35% MASH resolution with a fibrosis signal moves efinopegdutide into a real Phase 3 discussion. Anything below 25% resolution or a flat fibrosis curve makes this a discontinuation candidate given Merck's crowded internal pipeline. The commercial context favors patience over urgency: Merck's $65B revenue base means efinopegdutide would need to reach $2B+ peak sales to matter to the top line, and the MASH market is not yet proven at those levels (resmetirom's 2025 run rate is still ramping). Hanmi Pharmaceutical (KRX: 128940) retains milestone and royalty rights on efinopegdutide under the 2020 licensing deal; a Phase 3 go decision would trigger a material milestone payment (the $860M total pool includes both development and sales milestones, with individual disclosed payment amounts not itemized publicly) and is a positive catalyst for Hanmi's stock independent of Merck's top line [1]. The Boehringer survodutide Phase 3 readout in 2027 is the market-defining event; efinopegdutide's fate depends heavily on whether it can position as best-in-class dual agonist or gets locked out of the space. Check back after AASLD 2026 (November) for the first likely disclosure of NCT05877547 top-line results. If Merck says nothing there, the program is quietly deprioritized.